We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Biomarker May Predict Sudden Heart Failure

By LabMedica International staff writers
Posted on 13 Sep 2012
A blood test can predict who would benefit from Implantable Cardioverter Defibrillators (ICD), which are surgically implanted in heart failure patients to prevent sudden death,

The straightforward laboratory test can tell with high accuracy which patients will or will not require an ICD for the next 12 months that would prevent arrhythmia and its subsequent cardiac arrest. More...


Physicians at the Chicago College of Medicine (IL, USA) carried out a clinical trial on 180 adults participants of whom 135 of them had heart failure, and 45 were healthy individuals as the control group. They excluded people with inflammatory conditions, infections, and congenital heart disease. The blood test, called PulsePredic, detects alterations in the messenger ribonucleic acid (mRNA) for the sodium channel, voltage-gated, type V, alpha subunit (SCN5A) gene, which previous studies have shown to be closely linked with sudden death. The increase in the altered mRNA was found to be a good predictor of which patients were most likely to have a sudden death episode requiring defibrillation.

The scientists measured the SCN5A gene in white blood cells and heart muscle cells. By analyzing the alterations in the mRNA, they could predict who would have a sudden death episode where defibrillation would be required. The patients with heart failure who had arrhythmias that would cause sudden death were found to have considerably higher levels of these genetic mutations, compared to those with normal heartbeats. By measuring variant levels in the blood, they were able to predict surprisingly accurately who had arrhythmic risk, suggesting that it is possible to have a blood test for sudden death risk and the need for an ICD.

Certain proteins, called voltage-gated sodium channels, are responsible for generating the main current for the electrical signals in the heart. The SCN5A gene encodes for these proteins. Arrhythmias occur when there are rises or falls in the sodium current. Samuel C. Dudley, MD, PhD, chief cardiologist at the University of Illinois (Chicago, IL, USA), explained, “The test predicts whether you will have sudden death from heart failure and whether you will need a defibrillator in the next year." Professor Dudley is the CEO of ROS Technologies, Inc., the university’s spinoff company that will develop the blood test. The study was presented at the European Society of Cardiology Congress 2012, held in Munich (Germany).

Related Links:

Chicago College of Medicine
University of Illinois




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.